Trial
NCT04163432
Staggered, Chemo-Immunotherapy With Durvalumab, MEDI4736 Pemetrexed & Carboplatin (PC) for Metastatic Non-Squamous NSCLC
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
University of Utah
Collaborators
AstraZeneca
Condition
Non-Small Cell Lung Cancer Metastatic
Intervention
Durvalumab
Why stopped
Closed due to slow accrual
Provenance
Dataset: 2026-07-24 • Source: ClinicalTrials.gov API v2 • Last update: 2026-07-22